Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes of Novo Nordisk and Eli Lilly.

Still, both have ongoing plans to develop weight loss pills. If those plans pan out, the returns are likely to be enormous. So which of these dark horse competitors has the better shot at catching up to the leaders and staking out a claim for themselves? Let's dive in and find out.

Pfizer's most discussed weight loss program for the moment is danuglipron, and it's currently in phase 1 clinical trials. The pill is formulated for once-per-day administration, and the company has already stated an intent to proceed to phase 2 trials in the second half of this year. But danuglipron isn't exactly an asset that investors should get excited about.

Continue reading

Source Fool.com